NDC 0169-8100

ESPEROCT

Antihemophilic Factor (recombinant), Glycopegylated-exei

ESPEROCT is a Kit in the Plasma Derivative category. It is labeled and distributed by Novo Nordisk. The primary component is .

Product ID0169-8100_562f94e8-825f-4d7f-b93c-b783ac3a43bc
NDC0169-8100
Product TypePlasma Derivative
Proprietary NameESPEROCT
Generic NameAntihemophilic Factor (recombinant), Glycopegylated-exei
Dosage FormKit
Marketing Start Date2019-02-19
Marketing CategoryBLA / BLA
Application NumberBLA125671
Labeler NameNovo Nordisk
Active Ingredient Strength0
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 0169-8100-01

1 KIT in 1 KIT (0169-8100-01) * 4 mL in 1 VIAL, GLASS (0169-8101-90) * 4 mL in 1 SYRINGE, GLASS (0169-8008-98) * 4 mL in 1 VIAL, GLASS (0169-8101-11)
Marketing Start Date2019-02-19
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0169-8100-93 [00169810093]

ESPEROCT KIT
Marketing CategoryBLA
Application NumberBLA125671
Product TypePLASMA DERIVATIVE
Marketing Start Date2019-11-11

NDC 0169-8100-01 [00169810001]

ESPEROCT KIT
Marketing CategoryBLA
Application NumberBLA125671
Product TypePLASMA DERIVATIVE
Billing UnitEA
Marketing Start Date2019-02-19

Drug Details

NDC Crossover Matching brand name "ESPEROCT" or generic name "Antihemophilic Factor (recombinant), Glycopegylated-exei"

NDCBrand NameGeneric Name
0169-8100ESPEROCTantihemophilic factor (recombinant), glycopegylated-exei
0169-8150ESPEROCTantihemophilic factor (recombinant), glycopegylated-exei
0169-8200ESPEROCTantihemophilic factor (recombinant), glycopegylated-exei
0169-8300ESPEROCTantihemophilic factor (recombinant), glycopegylated-exei
0169-8500ESPEROCTantihemophilic factor (recombinant), glycopegylated-exei

Trademark Results [ESPEROCT]

Mark Image

Registration | Serial
Company
Trademark
Application Date
ESPEROCT
ESPEROCT
79152765 4697829 Live/Registered
Novo Nordisk Health Care AG
2014-07-24

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.